Aptose Biosciences (APS) Competitors C$0.42 +0.18 (+75.00%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlines APS vs. CZO, SBM, REUN, RVX, NEPT, ATE, KNE, IMV, IOT, and RVVShould you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Ceapro (CZO), Sirona Biochem (SBM), Reunion Neuroscience (REUN), Resverlogix (RVX), Neptune Wellness Solutions (NEPT), Antibe Therapeutics (ATE), Kane Biotech (KNE), IMV (IMV), Innovotech (IOT), and Revive Therapeutics (RVV). These companies are all part of the "biotechnology" industry. Aptose Biosciences vs. Ceapro Sirona Biochem Reunion Neuroscience Resverlogix Neptune Wellness Solutions Antibe Therapeutics Kane Biotech IMV Innovotech Revive Therapeutics Ceapro (CVE:CZO) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Do institutionals & insiders hold more shares of CZO or APS? 15.1% of Aptose Biosciences shares are held by institutional investors. 4.0% of Ceapro shares are held by company insiders. Comparatively, 17.1% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher valuation and earnings, CZO or APS? Ceapro has higher revenue and earnings than Aptose Biosciences. Ceapro is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCeaproC$9.63M1.83-C$4.71M-C$0.06-3.75Aptose BiosciencesN/AN/A-C$40.29M-C$5.78-0.07 Does the MarketBeat Community favor CZO or APS? Aptose Biosciences received 153 more outperform votes than Ceapro when rated by MarketBeat users. Likewise, 72.11% of users gave Aptose Biosciences an outperform vote while only 60.82% of users gave Ceapro an outperform vote. CompanyUnderperformOutperformCeaproOutperform Votes5960.82% Underperform Votes3839.18% Aptose BiosciencesOutperform Votes21272.11% Underperform Votes8227.89% Does the media prefer CZO or APS? In the previous week, Ceapro had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 1 mentions for Ceapro and 0 mentions for Aptose Biosciences. Ceapro's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score. Company Overall Sentiment Ceapro Neutral Aptose Biosciences Neutral Which has more volatility & risk, CZO or APS? Ceapro has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Is CZO or APS more profitable? Aptose Biosciences has a net margin of 0.00% compared to Ceapro's net margin of -48.89%. Ceapro's return on equity of -15.66% beat Aptose Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ceapro-48.89% -15.66% -11.30% Aptose Biosciences N/A -694.13%-136.29% SummaryCeapro beats Aptose Biosciences on 7 of the 13 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APS vs. The Competition Export to ExcelMetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$7.61MC$164.65MC$5.14BC$6.07BDividend Yield0.39%3.64%5.09%5.42%P/E Ratio-0.07115.5190.0526.16Price / SalesN/A18,239.951,117.141,332.85Price / Cash1.6012.7543.0482.30Price / Book-3.508.504.783.07Net Income-C$40.29M-C$20.67MC$120.31MC$295.24M7 Day Performance61.54%-1.04%-1.92%-2.48%1 Month Performance23.53%136.65%11.51%-0.78%1 Year Performance-86.09%137.57%30.61%34.67% Aptose Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APSAptose BiosciencesN/AC$0.42+75.0%N/A-86.7%C$7.61MN/A-0.0731News CoverageGap UpHigh Trading VolumeCZOCeaproN/AC$0.23-11.8%N/A+9.8%C$17.62MC$9.63M-3.75N/ANews CoverageGap DownSBMSirona BiochemN/AC$0.07-7.1%N/A-27.3%C$16.69MC$683,768.00-6.50N/AGap DownREUNReunion NeuroscienceN/AC$1.42-2.7%N/AN/AC$16.64MC$4.86M-0.43190Gap DownRVXResverlogixN/AC$0.06+9.1%N/A-21.4%C$16.62MN/A-1.1019NEPTNeptune Wellness SolutionsN/AN/AN/AN/AC$15.73MC$48.80M-0.08130Gap DownATEAntibe TherapeuticsN/AC$0.30+13.5%N/AN/AC$15.64MC$9.71M-0.8411KNEKane BiotechN/AC$0.11-8.7%N/A+33.3%C$13.91MC$2.74M-3.33N/AGap DownHigh Trading VolumeIMVIMVN/AC$1.12-1.8%N/AN/AC$13.12MC$23,000.00-0.1820IOTInnovotechN/AC$0.21+13.9%N/A+111.8%C$8.00MC$1.23M-18.001,620Negative NewsGap UpRVVRevive TherapeuticsN/AC$0.08+14.3%N/A+0.0%C$5.79MN/A-3.64N/AGap UpHigh Trading Volume Related Companies and Tools Related Companies CZO Competitors SBM Competitors REUN Competitors RVX Competitors NEPT Competitors ATE Competitors KNE Competitors IMV Competitors IOT Competitors RVV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:APS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
